Rasmus S Pedersen1, Per Damkier, Kim Brosen. 1. Clinical Pharmacology, University of Southern Denmark and Department of Biochemistry, Pharmacology and Genetics, Odense University Hospital, Odense, Denmark. rpedersen@health.sdu.dk
Abstract
AIMS: To determine the effect of CYP2C8 genotype and of fluvoxamine on the pharmacokinetics of rosiglitazone. METHODS:Twenty-three healthy subjects with the following genotypes were included in a two-phase, open-label, cross-over trial: CYP2C8*3/ *3 (n = 3), CYP2C8*1/ *3 (n = 10) and CYP2C8*1/ *1 (n = 10). In Phase A, the subjects were given 4 mg rosiglitazone as a single oral dose. In Phase B, the subjects were treated with multiple oral doses of 50 mg fluvoxamine maleate for 3 days prior to the single oral administration of 4 mg rosiglitazone. Plasma concentrations of rosiglitazone and relative amounts of N-desmethylrosiglitazone were measured in both phases for 24 h after drug administration. RESULTS: The pharmacokinetics of rosiglitazone and N-desmethylrosiglitazone were not significantly different between the CYP2C8 genotypic groups. Fluvoxamine caused a statistically significant (P = 0.0066) increase in the AUC(0-infinity) of rosiglitazone, with a geometric mean ratio of 1.21 [95% confidence interval (CI) 1.06-1.39]. The elimination half-life (t(1/2)) was also significantly higher (P = 0.0203) with a geometric mean ratio of 1.38 [95% CI 1.06-1.79]. The coadministration of fluvoxamine had no influence on the pharmacokinetics of N-desmethylrosiglitazone. CONCLUSION: The importance of the CYP2C8*3 mutation in the in vivo metabolism of rosiglitazone could not be confirmed. Fluvoxamine increased the AUC(0-infinity) and t(1/2) of rosiglitazone moderately and hence may be a weak inhibitor of CYP2C8.
RCT Entities:
AIMS: To determine the effect of CYP2C8 genotype and of fluvoxamine on the pharmacokinetics of rosiglitazone. METHODS: Twenty-three healthy subjects with the following genotypes were included in a two-phase, open-label, cross-over trial: CYP2C8*3/ *3 (n = 3), CYP2C8*1/ *3 (n = 10) and CYP2C8*1/ *1 (n = 10). In Phase A, the subjects were given 4 mg rosiglitazone as a single oral dose. In Phase B, the subjects were treated with multiple oral doses of 50 mg fluvoxamine maleate for 3 days prior to the single oral administration of 4 mg rosiglitazone. Plasma concentrations of rosiglitazone and relative amounts of N-desmethylrosiglitazone were measured in both phases for 24 h after drug administration. RESULTS: The pharmacokinetics of rosiglitazone and N-desmethylrosiglitazone were not significantly different between the CYP2C8 genotypic groups. Fluvoxamine caused a statistically significant (P = 0.0066) increase in the AUC(0-infinity) of rosiglitazone, with a geometric mean ratio of 1.21 [95% confidence interval (CI) 1.06-1.39]. The elimination half-life (t(1/2)) was also significantly higher (P = 0.0203) with a geometric mean ratio of 1.38 [95% CI 1.06-1.79]. The coadministration of fluvoxamine had no influence on the pharmacokinetics of N-desmethylrosiglitazone. CONCLUSION: The importance of the CYP2C8*3 mutation in the in vivo metabolism of rosiglitazone could not be confirmed. Fluvoxamine increased the AUC(0-infinity) and t(1/2) of rosiglitazone moderately and hence may be a weak inhibitor of CYP2C8.
Authors: Namrata Bahadur; Julian B S Leathart; Elaine Mutch; Dorothy Steimel-Crespi; Stuart A Dunn; Ron Gilissen; Jos Van Houdt; Jan Hendrickx; Geert Mannens; Hilde Bohets; Faith M Williams; Martin Armstrong; Charles L Crespi; Ann K Daly Journal: Biochem Pharmacol Date: 2002-12-01 Impact factor: 5.858
Authors: Umit Yasar; Stefan Lundgren; Erik Eliasson; Anna Bennet; Björn Wiman; Ulf de Faire; Anders Rane Journal: Biochem Biophys Res Commun Date: 2002-11-22 Impact factor: 3.575
Authors: Oranun Kerdpin; David J Elliot; Sanford L Boye; Donald J Birkett; Krongtong Yoovathaworn; John O Miners Journal: Biochemistry Date: 2004-06-22 Impact factor: 3.162
Authors: Elena García-Martín; Carmen Martínez; Beatriz Tabarés; Jesús Frías; José A G Agúndez Journal: Clin Pharmacol Ther Date: 2004-08 Impact factor: 6.875
Authors: C Verstuyft; S Morin; J Yang; M-A Loriot; V Barbu; R Kerb; U Brinkmann; P Beaune; P Jaillon; L Becquemont Journal: Ann Biol Clin (Paris) Date: 2003 May-Jun Impact factor: 0.459
Authors: Christina L Aquilante; Lisa A Kosmiski; David W A Bourne; Lane R Bushman; Elizabeth B Daily; Kyle P Hammond; Charles W Hopley; Rajendra S Kadam; Alexander T Kanack; Uday B Kompella; Merry Le; Julie A Predhomme; Joseph E Rower; Maha S Sidhom Journal: Br J Clin Pharmacol Date: 2013-01 Impact factor: 4.335
Authors: Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi Journal: Chem Res Toxicol Date: 2012-09-27 Impact factor: 3.739
Authors: Christina L Aquilante; Lane R Bushman; Shannon D Knutsen; Lauren E Burt; Lucille Capo Rome; Lisa A Kosmiski Journal: Hum Genomics Date: 2008-09 Impact factor: 4.639